Pharmaceuticals

Molecular Targeted Therapy Market Future Trends Influencing Growth Through 2030

May 1, 2026May 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Anticipated Rise In Market Value Of The Molecular Targeted Therapy Market During The Forecast Period?

The molecular targeted therapy market has experienced strong growth in recent years. This market is forecast to increase from $71.64 billion in 2025 to $77.89 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.7%. Historically, this expansion has been driven by advancements in cancer genomics research, the development of monoclonal antibodies, a rise in oncology drug approvals, the proliferation of hospital oncology centers, and the expansion of clinical trials.

The market size for molecular targeted therapy is forecast to exhibit substantial growth over the next few years. It is projected to expand to $107.64 billion by 2030, achieving a compound annual growth rate (CAGR) of 8.4%. This expansion during the forecast period is primarily driven by the increasing demand for personalized cancer treatment, wider adoption of next-generation sequencing, innovations in AI-driven drug discovery, the rising global oncology burden, and favorable targeted therapy reimbursement policies. Significant trends expected in this period include the broadening of precision oncology, enhanced adoption of biomarker-based therapies, the development of more targeted cancer drug pipelines, the integration of companion diagnostics, and the growing application of combination targeted therapies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24609&type=smp

Which Factors Are Influencing The Growth Of The Molecular Targeted Therapy Market?

The anticipated expansion of the molecular targeted therapy market is primarily fueled by the growing prevalence of personalized medicine. This healthcare strategy involves tailoring treatments and preventive measures to an individual’s unique genetic makeup, lifestyle choices, and environmental exposures. The surge in personalized medicine is largely due to the increasing availability of genetic data, which facilitates the development of therapies precisely matched to individual genomes, leading to improved effectiveness and reduced adverse reactions. Personalized medicine plays a crucial role in supporting molecular targeted therapy by identifying specific genetic mutations or biomarkers within a patient’s tumor, thereby enabling the selection of treatments that directly target these abnormalities. This methodology significantly enhances treatment accuracy while minimizing damage to healthy cells. As an illustration, the Personalized Medicine Coalition, a US-based hospital and health care organization, reported in February 2024 that the FDA sanctioned 16 novel personalized treatments for patients with rare diseases in 2023, an increase from 6 approvals in 2022. Consequently, the rise of personalized medicine stands as a significant driver for the growth of the molecular targeted therapy market.

What Are The Different Segment Types In The Molecular Targeted Therapy Market Segment Breakdown?

The molecular targeted therapy market covered in this report is segmented –

1) By Therapy Type: Monoclonal Antibodies, Small Molecule Inhibitors, Gene Therapy, Cell Therapy

2) By Mode Of Administration: Oral, Injectable, Topical, Intravenous

3) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Other Applications

4) By End-User: Hospitals, Clinics, Research Laboratories, Diagnostic Centers

Subsegments:

1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies

2) By Small Molecule Inhibitors: Tyrosine Kinase Inhibitors (TKIs), Proteasome Inhibitors, Poly Adenosine Diphosphate (ADP) Ribose Polymerase (PARP) Inhibitors, Mechanistic Target Of Rapamycin (mTOR) Inhibitors

3) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing

4) By Cell Therapy: Chimeric Antigen Receptor T-Cell Therapy, T-Cell Receptor (TCR) Therapy, Tumor-Infiltrating Lymphocytes (TILs) Therapy, Dendritic Cell Therapy

What Trends Are Influencing The Evolution Of The Molecular Targeted Therapy Market?

Key companies operating in the molecular targeted therapy market are prioritizing the development of advanced products, such as small molecule inhibitors, to enhance patient outcomes across various cancers and chronic ailments. Small molecule inhibitors are minute compounds capable of easily penetrating cells to suppress specific proteins that drive disease. For instance, in January 2025, Amgen Inc., a US-based pharmaceutical company, introduced Lumakras (sotorasib) in conjunction with Vectibix (panitumumab), which obtained approval from the US Food and Drug Administration (FDA), a US-based government organization. This therapy is formulated for adult patients with KRAS G12C-mutated metastatic colorectal cancer who have previously received fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, as confirmed by an FDA-approved test. This authorization stems from the Phase 3 CodeBreaK 300 trial, which indicated that the combination more than doubled progression-free survival compared to the investigated standard of care, positioning it as the first targeted therapy to demonstrate such a benefit in this chemorefractory patient group.

Who Are The Well-Known Companies In The Molecular Targeted Therapy Market?

Major companies operating in the molecular targeted therapy market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Amgen Inc., Regeneron Pharmaceuticals, Vertex Pharmaceuticals Incorporated, Novartis AG, Incyte Corporation, Exelixis Inc., IDEAYA Biosciences Inc., Prelude Therapeutics Incorporated, Gamida Cell Ltd., Adaptimmune Therapeutics plc, Engine Biosciences Pte. Ltd., Krystal Biotech Inc., Sotio Biotech a.s., Cybrexa Therapeutics Inc.

Get The Full Molecular Targeted Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/molecular-targeted-therapy-global-market-report

Which Region Represents The Largest Share Of The Molecular Targeted Therapy Market?

North America was the largest region in the molecular targeted therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the molecular targeted therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Molecular Targeted Therapy Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/molecular-targeted-therapy-global-market-report

Browse Through More Reports Similar to the Global Molecular Targeted Therapy Market 2026, By The Business Research Company

Targeted Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report

Cancer Immunotherapy Drug Discovery Outsourcing Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-drug-discovery-outsourcing-global-market-report

Advanced Therapeutics Pharmaceutical Outsourcing Market Report 2026

https://www.thebusinessresearchcompany.com/report/advanced-therapeutics-pharmaceutical-outsourcing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795